SJStanley C. Jordan

Stanley C. Jordan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Stanley C. Jordan has a total of 343 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Performance of the Integrative Box (iBox) Prognostication System in African American Kidney Transplant Recipients

    by Agathe Truchot, Yannis Lombardi, Marc Raynaud, Olivier Aubert, Gillian Divard, Thibaut Thalamas, Brad Astor, Didier Mandelbrot, Sandesh Parajuli, Kenneth A. Newell, et al.

    Key Points: The integrative box showed accurate discrimination, overall fit, and clinical utility in 3866 kidney transplant recipients from North America. Predictive performance was maintained in African American and non-African American kidney transplant recipients. These results support the robustness of the integrative box as a risk prediction tool. Background: The integrative box (iBox) is a validated prognostication system that predicts long-term death-censored graft loss in kidney transplant recipients, but its performance in the specific population of African American recipients has not been fully studied. Methods: We conducted a multicenter study including 3866 kidney transplant recipients from North America, of whom 1040 (27%) were African American, to assess the impact of race on the iBox's performance in predicting graft loss. Discrimination, calibration, overall fit, and clinical utility were evaluated in the whole cohort and in African American and non-African American recipients. Results: Performance metrics for the prediction of graft loss were similar in both subgroups in discrimination (C-index 0.80 [95% confidence interval (CI), 0.77 to 0.83] in African American recipients and 0.83 [95% CI, 0.81 to 0.85] in non-African American recipients, P = 0.07) and observed/expected ratios (1.08 [95% CI, 0.95 to 1.23] and 0.99 [95% CI, 0.88 to 1.10], respectively, P = 0.28). No significant interaction between iBox score values and race was found in multivariable analysis stratified by transplant center ( P = 0.24 for the interaction term). The results were consistent between the subgroups regardless of the equation used to estimate eGFR (Kidney Recipient Specific, CKD-Epidemiology Collaboration, or Modification of Diet in Renal Disease), but with variations in calibration across equations. Conclusions: The iBox prognostication system showed accurate discrimination, overall fit, and clinical utility up to 7 years after risk evaluation in African American and non-African American kidney transplant recipients, supporting its robustness in this population. Clinical Trial registry name and registration number: ClinicalTrials.gov, NCT03474003.

  • Open Access

    CTLA4-Ig + Anti-IL-6/IL-6R Treatment Results in Long-term Allograft Survival and Function in Highly HLA-sensitized Patients

    by Stanley C. Jordan, Sindhu Chandran, Noriko Ammerman, Edmund Huang, Jun Shoji, Xiaohai Zhang, Alice Peng, Bongha Shin, David Thomas, Reiad Najjar, et al.

    Background.: Highly HLA-sensitized (HS) patients are at increased risk for cell-mediated rejection (CMR)/antibody-mediated rejection (AMR) posttransplant and require intense immunosuppression to prevent these events. HS patients who experience calcineurin inhibitor (CNI) neuro/nephrotoxicity have few options as conversion to CNI-free regimens with cytotoxic T-lymphocyte-associated antigen (CTLA4)-Ig may risk donor specific antibody (DSA) rebound, CMR, and AMR. This remains an unmet medical need. Anti-interleukin (IL)-6/IL-6R treatment is useful in treating AMR and CMR and preventing rejection in HS patients after transplantation (tx). Here, we examined the utility of combining CTLA4-Ig with anti-IL-6/IL-6R treatment in 4 HS patients with CNI toxicity. Methods.: Four HS patients (3 with calculated panel reactive antibodies >97% at tx and 1 who developed chronic-active AMR (c-aAMR) 14 y post-tx were evaluated. Two patients, 100% calculated panel reactive antibody and +flow crossmatch at transplantation, were desensitized with plasma exchange + clazakizumab (anti-IL-6) and maintained on clazakizumab post-tx and transitioned from CNI to CTLA4-Ig. Two patients treated with anti-IL-6R (tocilizumab) were transitioned to CTLA4-Ig at 2 and 11 y post-tx. Patients were monitored for renal function (RF), DSA, de novo DSA (dn-DSA), immune cell subsets, and patient and graft survival. Results.: Clazakizumab and tocilizumab treated patients showed improvements in RF, with elimination of existing DSAs, except for 1 patient and no dn-DSAs (>6 y). We also saw reductions in CD8 + T EFF/MEM , T FH , B MEM , and NK cells post-CTLA4-Ig + Anti-IL-6/IL-6R treatment. T REG and B REG cell populations also increased, suggesting, but not confirming, possible immune modulation. Conclusions.: Combining CTLA4-Ig + anti-IL-6/IL-6R appears to offer benefits in sustaining RF, DSA reduction, possibly immune cell modulation, and prevention of dn-DSA. Importantly, CNI toxicity abated in all patients.

  • Open Access

    Butyrophilin 2A2 promotes T cell immunoregulation via CD45 phosphatase activation and protects against murine autoimmune glomerulonephritis and pregnancy loss

    by Shafat Ali, Anders H. Berg, Michifumi Yamashita, Ambart E. Covarrubias, Jordan Mundell, Pranali N. Shah, Ruan Zhang, Vincent Dupont, Bong-Ha Shin, Shen Yang, et al.

    B7 costimulatory family member Butyrophilin 2A2 (BTN2A2) is predominantly expressed by antigen presenting cells and regulates T cell immunity, but molecular mechanisms are unclear. Using immunoblots analyzing TCR-initiated signaling intermediaries, co-immunoprecipitation studies, confocal microscopy, structural modeling-guided mutational analyses, and microscale thermophoresis, we demonstrate that BTN2A2 directly interacts with CD45RO, resulting in CD45 retention within the immune synapse during TCR activation. Recombinant BTN2A2 increases murine CD4+Foxp3+ regulatory T cells (Treg) and reduces T helper 17 (Th17) cells in vitro through mechanisms dependent on CD45 phosphatase activity. BTN2A2 therapy alleviates disease severity in murine nephrotoxic glomerulonephritis and autoimmune miscarriage while increasing Treg/Th17 ratios. Analyses of BTN2A2-deficient animals show exacerbation of disease associated with reduced Treg/Th17 ratios. BTN2A2 functions analogously on human T cells suppressing Th17, Th1 and Th2 responses while inducing Tregs. Together, our studies identify BTN2A2 as a modulator of CD45RO signaling in T cells, providing insight into how BTN2A2 regulates T cell-dependent immune responses including those mediating autoimmunity and transplant rejection.


  • Evolving Therapeutic Approaches for Treatment of Antibody-Mediated Rejection in Renal Allograft Recipients

    by Stanley C. Jordan, Noriko Ammerman, Edmund Huang, Ashley Vo

    Antibody-mediated rejection (AMR) is now recognized as the primary cause of the decline of functional integrity and ultimately, graft failure in kidney transplants. Evolving understanding of effectors responsible for B-cell activation and plasma cell biology has led to the informed design of new therapeutics. Currently, several novel agents with varying mechanisms of action have emerged. These include imlifidase, FcRn inhibitors, anti-cytokine (IL-6/IL-6R) therapies, and plasma cell-directed therapies, especially anti-CD38s. As our understanding of critical effector pathways responsible for ARM grows, we now know that no single agent can control all facets of antibody generation and injury. The future of antibody-directed therapeutics will require protocols consisting of multiple agents positioned in a logical sequence to rapidly and durably remove pathogenic DSAs and block their re-emergence.

  • Open Access

    Tocilizumab Treatment for Microvascular Inflammation and Chronic Active Antibody-mediated Rejection in Kidney Transplantation

    by Edmund Huang, Michie Adjei, Alice Peng, Reiad Najjar, Jun Shoji, Sindhu Chandran, Ashley Vo, Stanley C. Jordan

    Background.: Interleukin-6 (IL-6) is an important driver of humoral immunity and a target for treatment of antibody-mediated rejection (AMR) in kidney transplantation. Data on IL-6 inhibition for treatment of AMR are mixed and their efficacy remains inconclusive. In this retrospective observational study, we investigated the association of monthly tocilizumab infusions with the trajectory of estimated glomerular filtration rate (eGFR) among kidney transplant patients with histologic features of chronic active AMR. Methods.: Through institutional database review, 85 adult kidney transplant patients with histologic features of chronic active AMR treated with monthly tocilizumab 8 mg/kg intravenous infusions were identified. Piecewise linear mixed effects models were fitted to compare eGFR trajectories 12 mo before and after tocilizumab initiation. Results.: The eGFR declined at a rate of –0.70 mL/min/1.73 m2/mo (95% confidence interval, –1.03 to –0.36) preceding tocilizumab initiation and stabilized after treatment onset to a slope of –0.07 (–0.35 to 0.21) mL/min/1.73 m2/mo (slope difference: 0.59 [0.22-0.97] mL/min/1.73 m2/mo, P = 0.002).The distribution of the sum mean fluorescence intensity of donor specific antibodies (DSA) among 65 DSA+ patients remained unchanged from baseline to 1 y after treatment; however, 14 of 65 DSA+ patients (22%) no longer had DSA at 1 y. There was 1 graft loss and 2 deaths, both COVID-19-related, by 12 mo after treatment onset. Conclusions.: This study suggests that monthly treatment with the anti-IL-6 receptor monoclonal antibody, tocilizumab, may stabilize allograft function among kidney transplant patients with chronic active AMR and that further studies to confirm its efficacy should be conducted.


  • Exosome-primed T cell immunity is facilitated by complement activation

    by Sara Alibrandi, Angela Clemens, Yansui Li, William J. Shufesky, Ashley Vo, Noriko Ammerman, Edmund Huang, Simon C. Watkins, Peter Heeger, Stanley Jordan, et al.


  • Open Access

    Back-table intra-arterial administration of C1 esterase inhibitor to deceased donor kidney allografts improves posttransplant allograft function: Results of a randomized double-blind placebo-controlled clinical trial

    by Edmund Huang, Noriko Ammerman, Ashley Vo, Jean Hou, Sanjeev Kumar, Nicole Badash, Ben Falk, Kathleen Hernando, Matthew Gillespie, Irene K. Kim, et al.


  • Open Access

    An Unusual Presentation of Bullous Skin Lesions During Pregnancy

    by Stanley C. Jordan, Bonnie Balzer, Susane Morrison, Allison Truong, Ananth Karumanchi

    Here, we present a 33-years-old pregnant female who at 27-weeks gestation developed an unusual rash on her left knee after a spider bite. The rash rapidly became systemic requiring admission and treatment with high-dose steroids. Patient rapidly developed complications of steroid therapy and saw no benefits in reducing the activity of the rash of symptoms of itching. A repeat biopsy showed linear fluorescence along the dermal epidermal junction with C3 (strong) and IgG (weak) suggestive of pemphigus gestationis (PG). After balancing concerns for the health of the mother and risk for disease transmission to the child, we decided to treat the patient with high-dose intravenous immunoglobulin (IVIg). This resulted in rapid remission of disease and delivery of a healthy child without evidence of PG at 36-weeks gestation. A discussion of the mechanism(s) of action of IVIg that were salutary in this case is presented. Importantly, we discuss the likely benefits of IVIg in saturation of the Fc-receptor neonatal IgG recycling and preservation system in accelerating the degradation of pathogenic IgGs and the inhibitory of effects of IVIg on C3 activation which was the predominant immunoreactant in skin biopsy. The patient recovered completely after the fourth monthly IVIg infusion and continues to do well.